Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

<p>Abstract</p> <p>Background</p> <p>Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%....

Full description

Bibliographic Details
Main Authors: Strutton David R, Farkouh Raymond A, Rubin Jaime L, McGarry Lisa J, Loiacono Paul M, Klugman Keith P, Pelton Steven I, Gilmore Kristen E, Weinstein Milton C
Format: Article
Language:English
Published: BMC 2012-08-01
Series:BMC Infectious Diseases
Subjects:
Pneumococcal conjugate vaccine
Catch-up vaccination
Pneumococcal
PCV13
13-valent
Online Access:http://www.biomedcentral.com/1471-2334/12/175

Internet

http://www.biomedcentral.com/1471-2334/12/175

Similar Items